Novo Nordisk’s IDegLira, which is a combination of an ultralong acting basal insulin analogue Insulin degludec and glucagonlike peptide 1 agonist Liraglutide, for the treatment of type 2 diabetes, is all set to be reviewed by an FDA advisory panel on May 24, 2016.